Vir Biotechnology, Inc. (VIR)
| Market Cap | 5.14B |
| Revenue (ttm) | 72.63M |
| Net Income (ttm) | -390.34M |
| Shares Out | 130.04M |
| EPS (ttm) | -14.64 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $39.33 |
| Previous Close | $39.11 |
| Change ($) | 0.22 |
| Change (%) | 0.56% |
| Day's Open | 39.46 |
| Day's Range | 38.30 - 41.11 |
| Day's Volume | 304,301 |
| 52-Week Range | 25.31 - 141.01 |
– Rolling review will evaluate sotrovimab in adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19 –
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -473.91% and -98.84%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN FRANCISCO, April 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the first quarter end...
Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient in a Phase 2 trial evaluating BRII-835 (VIR-2218) in combination wi...
DURHAM, N.C. & BEIJING & SAN FRANCISCO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Brii Biosciences (Brii Bio), Vir Biotechnology, Inc. (Nasdaq: VIR), and VBI Vaccines Inc. (Nasdaq: VBIV) today announced that ...
Vir is developing treatments in billion-dollar markets.
The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.
GSK and Vir continue discussions with global regulators to make VIR-7831 available to patients with COVID-19 GSK and Vir continue discussions with global regulators to make VIR-7831 available to patient...
One of the three clearly has the most upside potential.
– Growing body of evidence suggests monoclonal antibodies that target a conserved epitope have the potential to be highly effective against SARS-CoV-2 and associated known mutations –
Which stock has more potential for growth over the next year? Let's look to the stars for an answer.
SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat a...
Vir Biotechnology Inc (NASDAQ: VIR) has announced new preclinical data of VIR-7831, the company's investigational monoclonal antibody (mAb) against SARS-CoV-2. The new data showed that the antibody main...
– Data add to growing body of pre-clinical evidence demonstrating that VIR-7831 maintains activity against all known circulating variants of concern –
Eli Lilly And Co (NYSE: LLY), Vir Biotechnology Inc (NASDAQ: VIR), and GlaxoSmithKline plc (NYSE: GSK) have announced topline data from the expanded Phase 2 BLAZE-4 trial evaluating bamlanivimab co-admi...
INDIANAPOLIS and SAN FRANCISCO and LONDON, March 29, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced...
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc. (NASDAQ: VIR) have submitted an application to the Food and Drug Administration requesting emergency use authorization for VIR-7831, an investi...
GlaxoSmithKline and Vir Biotechnology applied for an emergency use authorization from the Food and Drug Administration for their monoclonal antibody drug.
LONDON and SAN FRANCISCO, March 26, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the submission of an application to the U.S. Fo...
NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are advised to co...
New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are...
Short-term investors may not see the long-term potential.
NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are advised to c...
Last week, Vir Biotechnology Inc's (NASDAQ: VIR) and its collaborating partner GlaxoSmithKline Plc (NYSE: GSK) announced interim Phase 3 data from COVID-19 antibody therapy, named VIR-7831 (GSK4182136)....
New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are...
Vir Biotechnology, Inc. (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be mor...
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are advised to c...
Investors are excited about the potential of the company's investigational coronavirus therapy.
VIR Biotech CEO on its positive Covid antibody drug results
CNBC's Meg Tirrell discusses VIR Biotechnology's antibody drug results and what it can do to aid the Covid pandemic with VIR Biotech CEO George Scangos.
GlaxoSmithKline and Vir Biotechnology said Wednesday their antibody drug reduced the risk of hospitalization and death in high-risk Covid-19 patients — and Vir stock catapulted Thursday. The post Vir St...
Vir/GSK's COVID-19 Antibody Therapy Cuts Hospitalization, Deaths by 85%, Seeks FDA Emergency Use Nod
An Independent Data Monitoring Committee (IDMC) has recommended that the Phase 3 COMET-ICE trial, evaluating VIR-7831 (GSK4182136) as monotherapy for COVID-19, stop enrollment due to evidence of profoun...
– Independent Data Monitoring Committee recommends stopping Phase 3 COMET-ICE trial early given an 85% reduction in hospitalization or death –
New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Vir Biotechnology, Inc. ("Vir" or the "Company") (NASDAQ: VIR). Such investors are ...
The relationship could result in a marriage down the line.
The biotech's pipeline gets a seal of approval.
Bearish commentary from an analyst may be to blame.
Investors need to pay close attention to Vir Biotechnology (VIR) stock based on the movements in the options market lately.
VIR stock is plunging on some pretty unfavorable news about a trial being suspended for the company's prospective Covid-19 vaccine. The post VIR Stock: Why Vir Biotechnology Is Plunging Today appeared f...
The company provided a discouraging regulatory update.
Vir Biotechnology Inc (NASDAQ: VIR) and GlaxoSmithKline plc (NYSE: GSK) have provided an update on the VIR-7831 (GSK4182136) arm of NIH-sponsored ACTIV Program Phase 3 trial in hospitalized adults with ...
The battle against Covid-19 is about to get uglier. Coronavirus mutations threaten to undercut a year's worth of work upholding Covid stocks like Pfizer, Moderna and Regeneron Pharmaceuticals.
SAN FRANCISCO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended Decembe...
Vir Biotechnology, Inc. (VIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaxo (GSK)/Vir Biotech expands their existing coronavirus collaboration for developing new monoclonal antibody candidates for influenza and other respiratory viruses.
The biotech will get $345 million through an upfront payment and equity investment.
The biotech is expanding its collaboration with a big partner.
Vir Biotech CEO on the expanded GSK partnership
George Scangos, CEO of VIR Biotechnology, joins "Squawk Alley" to discuss the company's expanded partnership with GlaxoSmithKline as well as Covid antibody treatments. For access to live and exclusive v...
– Companies applying their combined expertise in immunology and infectious diseases to accelerate the development of promising monoclonal antibody candidates for influenza –
SAN FRANCISCO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and...
About VIR
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Bri... [Read more...]
| Industry Biotechnology | IPO Date Oct 11, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol VIR |
Financial Performance
In 2020, VIR's revenue was $76.37 million, an increase of 843.86% compared to the previous year's $8.09 million. Losses were -$298.67 million, 71.0% more than in 2019.
Analyst Forecasts
According to 8 analysts, the average rating for VIR stock is "Buy." The 12-month stock price forecast is 88.40, which is an increase of 124.76% from the latest price.